Kadono, Y.; Kawaguchi, S.; Nohara, T.; Shigehara, K.; Izumi, K.; Kamijima, T.; Seto, C.; Takano, A.; Yotsuyanagi, S.; Nakagawa, R.; Miyagi, T.; Aoyama, S.; Asahi, H.; Fukuda, R.; Mizokami, A. Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST. Urol J 2021, 19, 202-208.